Comparison of Atypical Antipsychotics
|
|
- Peter Bridges
- 5 years ago
- Views:
Transcription
1 PL Detail-Document # This PL Detail-Document gives subscribers additional insight related to the Recommendations published in PHARMACIST S LETTER / PRESCRIBER S LETTER October 2012 Comparison of Atypical Antipsychotics Second-generation or atypical antipsychotics have a lower propensity than the first generation agents to cause extrapyramidal side effects. Clozapine may be the most effective atypical for schizophrenia, but its use is limited due to the risk of agranulocytosis. 1,21 All carry black box warnings regarding mortality risk in dementia-related psychosis, and suicidality if indicated for depression. Atypicals pose varying risks of QT prolongation, drug interactions, and metabolic adverse effects. The newest agents are asenapine (Saphris), paliperidone (Invega, Invega Sustenna), iloperidone (Fanapt), and lurasidone (Latuda). Thus, their side effect profiles are not as well-characterized as the older agents. Extrapyramidal side effects seem lowest with iloperidone and quetiapine (Seroquel), and higher with risperidone and paliperidone Hyperprolactinemia, associated with sexual dysfunction, gynecomastia, and irregular periods, seems most common with risperidone and paliperidone. 26 Side effects, cost, and dosing frequency, are all considerations in choice of agent. The chart below compares atypicals in regard to indications, dosing, metabolic side effects, sedation, QT prolongation, CYP3A4 metabolism, and cost. FDA-approved pediatric indications/doses are available in our PL Detail-Document, Atypical Antipsychotics in Kids. NOTE: *Usual or target daily adult dosage range may not include initial and maximum doses. Use lowest effective dose. Maximum doses of oral aripiprazole, lurasidone, olanzapine, paliperidone, quetiapine XR, and risperidone are approved for once-daily administration. Divide asenapine, iloperidone, and ziprasidone twice daily. Aripiprazole (Abilify) c,k,l 10 mg $ Asenapine (Saphris) m 20 mg $ Dosage Range (mg/day)*,a Schizophrenia: mg Bipolar disorder (acute manic or mixed episodes; maintenance): 15 mg Depression (adjunct): 5-10 mg Schizophrenia: 10 mg (acute), 20 mg (maintenance) Bipolar disorder (acute manic or mixed episodes): mg For sublingual use. Avoid food or drink for 10 min. after administration. Metabolic Adverse Effects 1,14-17,21,24,a QT Weight Diabetes Dyslipidemia Prolonging a,n,18 Gain Risk Low to None None Yes Yes Low Low to Low to CYP3A4 Sedation a,19 Metabolism a Low to Yes d Yes (minor) Low to
2 (PL Detail-Document #281006: Page 2 of 6) Clozapine (Clozaril, generics) 300 mg $ Iloperidone (Fanapt) 12 mg $ Lurasidone (Latuda) 40 mg $ Olanzapine (Zyprexa, generics) f,k 10 mg $15.75 Paliperidone (Invega) g 6 mg $ Dosage Range (mg/day) a, * Schizophrenia (treatment-resistant): mg Recurrent suicidal behavior risk reduction in schizophrenia & schizoaffective disorder: mg Schizophrenia: mg Schizophrenia: mg Take with food. Schizophrenia: mg Bipolar disorder (acute manic or mixed episodes; maintenance): 5-20 mg Depression (associated with bipolar disorder), with fluoxetine: mg Depression (treatment-resistant), with fluoxetine: 5-20 mg Schizophrenia: 3-12 mg Schizoaffective disorder (acute): 3-12 mg Sedation a,19 Metabolic Adverse Effects 1,14-17,21,24,a QT CYP3A4 Weight Diabetes Dyslipidemia Prolonging a,n,18 Metabolism a Gain Risk High High High Yes Yes High Low Low Yes e Yes Low Low Low Low or No Yes High High High Yes No Low Low None Yes d Yes (minor) Low
3 (PL Detail-Document #281006: Page 3 of 6) Quetiapine (Seroquel, generics) 400 mg $32.46 Dosage Range (mg/day) a, * Schizophrenia: mg Bipolar disorder (acute depression): 300 mg Bipolar disorder (acute mania, maintenance [adjunct]): mg Metabolic Adverse Effects 1,14-17,21,24,a Weight Gain Diabetes Risk Dyslipidemia QT Prolonging a,n,18 CYP3A4 Metabolism a Sedation a,19 Yes d Yes Quetiapine (Seroquel XR) 400 mg $ Schizophrenia: mg Bipolar disorder (acute depression): 300 mg Bipolar disorder (manic or mixed episodes; maintenance [adjunct]): mg Major depressive disorder [adjunct]: mg Take without food or with a light meal (about 300 kcal). Risperidone (Risperdal, generics) h,k,l 4 mg $11.22 Schizophrenia: 4-8 mg Bipolar disorder (acute manic or mixed episodes): 1-6 mg Low Yes No Low
4 (PL Detail-Document #281006: Page 4 of 6) Ziprasidone (Geodon, generics) i 80 mg $ Dosage Range (mg/day) a, * Schizophrenia: mg Bipolar disorder (acute manic or mixed episodes; maintenance [adjunct]): mg Take with food. Metabolic Adverse Effects 1,14-17,21,24,a Weight gain Low or Diabetes Risk Dyslipidemia QT Prolonging a,n,18 CYP3A4 Metabolism a Sedation a,19 None None Yes j Yes Low a. Per FDA-approved product labeling and our PL Chart, Drug-induced Long QT Interval. 2-7,9-11,13,20 A yes in the QT column means, at minimum, QT prolongation has been reported in patients taking the medication, regardless of causality. Some of these medications have contraindications or recommendations to avoid use related to QT prolongation (see footnotes). b. Wholesale Average Cost (WAC) of one-month supply of daily oral dose specified (lowest cost generic, when available). c. Aripiprazole is available as an IM formulation for agitation associated with schizophrenia or bipolar disorder (usual dose 9.75 mg [may consider 5.25 mg]; may re-dose after two hours if needed; 30 mg maximum daily dose). 2 d. Avoid use with medications that prolong the QT interval and in patients with risk factors for QT prolongation. 3,7-10 e. Consider as second-line antipsychotic due to capacity to prolong QT interval. Avoid use with medications that prolong QT interval, and use caution and consider dose reduction with drugs that inhibit its metabolism. Monitor potassium and magnesium in patients at risk of electrolyte disturbances. 5 f. Olanzapine is available as a short-acting IM formulation (Zyprexa IntraMuscular) and a long-acting IM formulation (Zyprexa Relprevv). 6,27 Zyprexa IntraMuscular is indicated for agitation associated with schizophrenia or bipolar I mania. Usual dose is 10 mg (lower dose [2.5, 5, 7.5 mg] may be given). Max daily dose 30 mg (i.e., 10 mg two hours after first dose, and 10 mg four hours after second dose). 6 Zyprexa Relprevv is indicated for acute and maintenance treatment of schizophrenia in patients with established tolerability to oral olanzapine. Give the first dose in a facility equipped to handle medical emergencies. Monitor for sedation and delirium. During the first eight weeks of therapy, the usual dose is 210 mg every two weeks or 405 mg every four weeks (corresponding to an oral dose of 10 mg once daily), or 300 mg every two weeks (corresponding to an oral dose of 15 to 20 mg once daily). Start with 150 mg every four weeks for elderly or debilitated patients, or patients who may have slower olanzapine metabolism or extra sensitivity to its effects, including hypotension. Maintenance doses of Zyprexa Relprevv are 150, 210, or 300 mg every two weeks (corresponding to oral doses of 10, 15, or 20 mg once daily, respectively) or 300 or 405 mg every four weeks (corresponding to oral doses of 10 or 15 mg once daily, respectively). 27 g. Paliperidone is available as an extended-release IM formulation (Invega Sustenna) for acute and maintenance treatment of schizophrenia in patients with established tolerability to paliperidone or risperidone. Initial dose is 234 mg, then 156 mg one week later, then 39 mg to 234 mg monthly. 8 h. Risperidone is available as a long-acting IM formulation (Risperdal Consta) for schizophrenia and bipolar disorder (25 mg/dose every two weeks; 50 mg maximum dose every two weeks). 12 i. Ziprasidone is available as IM formulation for acute agitation in schizophrenic patients (10-20 mg/dose; Doses of 10 mg may be given every two hours. Doses of 20 mg may be given every four hours. 40 mg maximum daily dose). 13 j. Consider as second-line antipsychotic due to capacity to prolong QT interval. Contraindicated in long QT syndrome, recent myocardial infarction, uncompensated heart failure, and with medications that prolong the QT interval. Avoid use in patients with bradycardia or arrhythmias. Check electrolytes at baseline and periodically in patients at risk for electrolyte disturbances. Ensure normal potassium and magnesium levels. 13
5 (PL Detail-Document #281006: Page 5 of 6) k. Also available as an orally disintegrating tablet. L. Also available as an oral solution. m. Sublingual formulation. n. Aripiprazole, olanzapine, and lurasidone (Latuda) may pose relatively lower torsades risk vs other antipsychotics based on product labeling and literature review. Risperidone may pose more moderate risk vs higher-risk atypical antipsychotics. Users of this PL Detail-Document are cautioned to use their own professional judgment and consult any other necessary or appropriate sources prior to making clinical judgments based on the content of this document. Our editors have researched the information with input from experts, government agencies, and national organizations. Information and internet links in this article were current as of the date of publication.
6 (PL Detail-Document #281006: Page 6 of 6) Project Leader in preparation of this PL Detail- Document: Melanie Cupp, Pharm.D., BCPS References 1. American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. Consensus Development Conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004;27: Product information for Abilify. Bristol-Myers Squibb Company. Princeton, NJ February 3. Product information for Saphris. Schering-Plough Corporation. Kenilworth, NJ October Product information for Clozaril. Novartis Pharmaceuticals Corporation. East Hanover, NJ October Product information for Fanapt. Vanda Pharmaceuticals Inc. Rockville, MD January 6. Product information for Zyprexa. Eli Lilly and Company. Indianapolis, IN June Product information for Invega. Ortho-McNeil Janssen Pharmaceuticals, Inc. Titusville, NJ June Product information for Invega Sustenna. Ortho- McNeil Janssen Pharmaceuticals, Inc. Titusville, NJ August 9. Product information for Seroquel. AstraZeneca Pharmaceuticals LP. Wilmington, DE November Product information for Seroquel XR. AstraZeneca Pharmaceuticals LP. Wilmington, DE November Product information for Risperdal. Ortho-McNeil Janssen Pharmaceuticals, Inc. Titusville, NJ August 12. Product information for Risperdal Consta. Ortho- McNeil Janssen Pharmaceuticals, Inc. Titusville, NJ June 13. Product information for Geodon. Pfizer Inc. NY, NY December Bishara D, Taylor D. Upcoming agents for the treatment of schizophrenia: mechanism of action, efficacy and tolerability. Drugs 2008;68: Potkin SG, Cohen M, Panagides J. Efficacy and tolerability of asenapine in acute schizophrenia: a placebo- and risperidone-controlled trial. J Clin Psychiatry 2007;68: Kane JM, Lauriello J, Laska E, et al. Long-term efficacy and safety of iloperidone: results from 3 clinical trials for the treatment of schizophrenia. J Clin Psychopharmacol 2008;28 (2 Suppl 1):S29-S Fowler JA, Bettinger TL, Argo TR. Paliperidone extended-release tablets for the acute and maintenance treatment of schizophrenia. Clin Ther 2008;30: PL Detail-Document, Drug-induced Long QT Interval. Pharmacist s Letter/Prescriber s Letter. January 19. Miller DD. Atypical antipsychotics: sleep, sedation, and efficacy. Prim Care Companion J Clin Psychiatry 2004;6(Suppl 2): Product information for Latuda. Sunovion Pharmaceuticals Inc. Marlborough, MA May 21. Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353: Rummel-Kluge C, Komossa K, Schwarz S, et al. Second-generation antipsychotic drugs and extrapyramidal side effects: a systematic review and meta-analysis of head-to-head comparisons. Schizophr Bull 2012;38: Caccia S, Pasina L, Nobili A. New atypical antipsychotics for schizophrenia: iloperidone. Drug Des Devel Ther 2010;4: McDonagh MS, Peterson K, Carson S, et al. Drug class review: atypical antipsychotic drugs: final report update 2 [Internet]. Portland, (OR): Oregon Health & Science University, 2008 Jun. C.pdf. (Accessed January 7, 2011). 25. Chwieduk CM, Keating GM. Paliperidone extended release; a review of its use in the management of schizophrenia. Drugs 2010;70: Correll CU. Antipsychotic use in children and adolescents: minimizing adverse effects to maximize outcomes. J Am Acad Child Adolesc Psychiatry 2008;47: Product information for Zyprexa Relprevv. Eli Lilly and Company. Indianapolis, IN August Cite this document as follows: PL Detail-Document, Comparison of Atypical Antipsychotics. Pharmacist s Letter/Prescriber s Letter. October Evidence and Recommendations You Can Trust 3120 West March Lane, P.O. Box 8190, Stockton, CA ~ TEL (209) ~ FAX (209) Subscribers to the Letter can get PL Detail-Documents, like this one, on any topic covered in any issue by going to or
Antipsychotics in Bipolar
Use of Second-Generation Antipsychotics in Bipolar Disorder: A Practical Guide Flavio Guzman, MD Editor Psychopharmacology Institute This practical guide is an update on the use of second-generation antipsychotics
More informationSTEP THERAPY CRITERIA
DRUG CLASS PRODUCTS) BRAND NAME (BRAND ONLY) (generic) STEP THERAPY CRITERIA ATYPICAL ANTIPSYCHOTICS (BRAND ONLY ABILIFY (AL TABLET & AL SOLUTION ONLY) (aripiprazole) FANAPT (BRAND ONLY) (iloperidone)
More informationPharmacy Medical Necessity Guidelines: Antipsychotic Medications
Pharmacy Medical Necessity Guidelines: Effective: October 1, 2016 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy (RX) or Medical (MED) Benefit
More informationSlide 1. Slide 2. Slide 3. About this module. About this module. Antipsychotics: The Essentials Module 5 A Primer on Selected Antipsychotics
Slide 1 Antipsychotics: The Essentials Module 5 A Primer on Selected Antipsychotics Flavio Guzmán, MD Slide 2 About this module 13 antipsychotics will be studied 3 first generation antipsychotics 10 second
More informationPharmacy Medical Necessity Guidelines: Atypical Antipsychotic Medications. Effective: December 12, 2017
Pharmacy Medical Necessity Guidelines: Effective: December 12, 2017 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy (RX) or Medical (MED)
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Reference Number: HIM.PA.59 Effective Date: 12/14 Last Review Date: 08/17 Line of Business: Health Insurance Marketplace Coding Implications Revision Log See Important Reminder at the
More informationPharmacy Medical Necessity Guidelines: Atypical Antipsychotic Medications. Effective: February 20, 2017
Pharmacy Medical Necessity Guidelines: Effective: February 20, 2017 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy (RX) or Medical (MED)
More informationDrug Use Criteria: Atypical Antipsychotics (oral)
Texas Vendor Drug Program Drug Use Criteria: Atypical Antipsychotics (oral) Publication History 1. Developed: February 1997 2. Revised: September 2017; September 2015; December 2013; February 2012; June
More informationDrug Class Review Second Generation Antipsychotic Drugs
Drug Class Review Second Generation Antipsychotic Drugs Final Update 4 Report November 2013 The purpose of reports is to make available information regarding the comparative clinical effectiveness and
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Invega Sustenna, Invega Trinza) Reference Number: CP.PHAR.291 Effective Date: 12.01.16 Last Review Date: 08.18 Line of Business: Medicaid See Important Reminder at the end of this policy
More informationPharmacy Medical Necessity Guidelines: Antipsychotic Medications
Pharmacy Medical Necessity Guidelines: Antipsychotic Medications Effective: July. 1, 2016 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy
More informationAntipsychotics Prior Authorization Criteria for Louisiana Fee for Service and MCO Medicaid Recipients
Antipsychotics Prior Authorization Criteria for Louisiana Fee for Service and MCO Medicaid Recipients Preferred Agents (Oral) a Amitriptyline/Perphenazine (Generic) Aripiprazole Tablet (Generic) b Chlorpromazine
More informationPharmacy Medical Necessity Guidelines: Antipsychotic Medications
Pharmacy Medical Necessity Guidelines: Effective: April 1, 2018 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy (RX) or Medical (MED) Benefit
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Saphris) Reference Number: CP.PMN.15 Effective Date: 12.01.14 Last Review Date: 02.18 Line of Business: Commercial, Health Insurance Marketplace, Medicaid Revision Log See Important Reminder
More informationClinical Policy: Olanzapine Long-Acting Injection (Zyprexa Relprevv) Reference Number: CP.PHAR.292 Effective Date: Last Review Date: 08.
Clinical Policy: (Zyprexa Relprevv) Reference Number: CP.PHAR.292 Effective Date: 12.01.16 Last Review Date: 08.18 Line of Business: Medicaid See Important Reminder at the end of this policy for important
More informationAntipsychotics. Something Old, Something New, Something Used to Treat the Blues
Antipsychotics Something Old, Something New, Something Used to Treat the Blues Objectives To provide an overview of the key differences between first and second generation agents To an overview the newer
More informationMedication Audit Checklist- Antipsychotics - Atypical
Medication Audit checklist Page 1 of 7 10-2018 Audit number: Client number: Ordering Provider: INDICATIONS 1) Disorders with psychotic symptoms (schizophrenia, schizoaffective disorder, manic disorders,
More informationMichael J. Bailey, M.D. OptumHealth Public Sector
Michael J. Bailey, M.D. OptumHealth Public Sector LIHP Quality Charter To ensure the quality of care delivered to enrollees in San Diego County Assistance Programs, such as County Medical Services (CMS)
More informationSlide 1. Slide 2. Slide 3. Risperidone Binding Profile. Risperidone Prescribing Facts. Risperidone Prescribing Facts
Slide 1 Risperidone Binding Profile (high affinity for D2 receptors) a 1 antagonist a 2 antagonist Slide 2 Risperidone Prescribing Facts 2 8 mg/day for acute psychosis and bipolar disorder 0.5-2 mg /day
More informationAbbreviated Class Review: Long-Acting Injectable Antipsychotics
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationAbbreviated Class Review: Long-Acting Injectable Antipsychotics
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationMEDICAL ASSISTANCE HANDBOOK PRIOR AUTHORIZATION OF PHARMACEUTICAL SERVICES. I. Requirements for Prior Authorization of Antipsychotics
MEDICAL ASSISTANCE HBOOK PRI AUTHIZATION OF PHARMACEUTICAL SERVICES I. Requirements for Prior Authorization of Antipsychotics A. Prescriptions That Require Prior Authorization Prescriptions for Antipsychotics
More informationCurrent Non-Preferred Agents
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationObjectives. Antipsychotics 7/25/2016. LeadingAge Florida 53rd Annual Convention & Exposition
Reducing the Use of Antipsychotics in Long Term Care Communities Alan W. Obringer RPh, CPh, CGP Executive Director Senior Care Pharmacy Objectives Recognize the clinical evidence for the need to change
More informationStep Therapy Group. Atypical Antipsychotic Agents
Atypical Antipsychotic Agents Any beneficiary newly enrolled into Community Care, Inc. currently receiving aripiprazole, aripiprazole ODT, risperidone, risperidone ODT, olanzapine, olanzapine ODT, quetiapine,
More informationNEWER ATYPICAL ANTIPSYCHOTICS: NOVEL IDEAS OR
NEWER ATYPICAL ANTIPSYCHOTICS: NOVEL IDEAS OR METOOS? Sanaz Farhadian, Pharm.D., BCPP Clinical Psychiatric Pharmacist Veterans Affairs Healthcare System, San Diego, CA OBJECTIVES Discuss new antipsychotics
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Abilify Maintena, Aristada, Aristada Initio) Reference Number: CP.PHAR.290 Effective Date: 12.01.16 Last Review Date: 08.18 Line of Business: Medicaid Coding Implications Revision Log
More informationIOWA MEDICAID DRUG UTILIZATION REVIEW COMMISSION 100 Army Post Road (515)
IOWA MEDICAID DRUG UTILIZATION REVIEW COMMISSION 100 Army Post Road (515) 974-3131 -866-626-0216 Brett Faine, Pharm.D. Larry Ambroson, R.Ph. Casey Clor, M.D. Professional Staff: Mark Graber, M.D., FACEP
More informationPL CE LIVE February 2011 Forum
February 2011 PL CE LIVE Kristin W. Weitzel, Pharm.D., CDE, FAPhA Associate Editor and Director of Editorial Projects Pharmacist s Letter/Prescriber s Letter Atypical Antipsychotics Atypical Antipsychotics
More informationRe: Safety data on Zyprexa (olanzapine) and Symbyax (olanzapine and fluoxetine HCl capsules) Hyperglycemia, Weight Gain, and Hyperlipidemia
www.lilly.com Eli Lilly and Company Lilly Corporate Center Indianapolis, Indiana 46285 U.S.A. Phone 317 276 2000 October 5, 2007 Re: Safety data on Zyprexa (olanzapine) and Symbyax (olanzapine and fluoxetine
More informationNebraska Medicaid Criteria. Abilify Maintena
Nebraska Medicaid Criteria All initial and renewal authorizations are for 12 months in duration. Abilify Maintena *Criteria for Authorization for Abilify Maintena The individual has a current DSM diagnosis
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Invega) Reference Number: CP. PMA.10.11.19 Effective Date: 10.06.16 Last Review Date: 04.18 Line of Business: CenpaticoMedicaid Revision Log See Important Reminder at the end of this
More informationAntipsychotic Medications Age and Step Therapy
Market DC *- Florida Healthy Kids Antipsychotic Medications Age and Step Therapy Override(s) Approval Duration Prior Authorization 1 year Quantity Limit *Virginia Medicaid See State Specific Mandates *Indiana
More informationA Brief Overview of Psychiatric Pharmacotherapy. Joel V. Oberstar, M.D. Chief Executive Officer
A Brief Overview of Psychiatric Pharmacotherapy Joel V. Oberstar, M.D. Chief Executive Officer Disclosures Some medications discussed are not approved by the FDA for use in the population discussed/described.
More informationDebra Brown, PharmD, FASCP Pharmaceutical Consultant II Specialist. HMS Training Webinar January 27, 2017
Debra Brown, PharmD, FASCP Pharmaceutical Consultant II Specialist HMS Training Webinar January 27, 2017 1 Describe nationwide prevalence and types of elderly dementia + define BPSD Define psychotropic
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Vraylar) Reference Number: CP.PMN.91 Effective Date: 11.16.16 Last Review Date: 02.18 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this policy
More informationIndiana Medicaid Drug Utilization Review Board Newsletter
Indiana Medicaid Drug Utilization Review Board Newsletter Volume 15 Issue 1 April 2012 Indiana Medicaid DUR Board Room W382 Indiana State Government Center, South 402 West Washington Street Indianapolis,
More informationDosing & Administration
Dosing & Administration REAL LIFE. REAL RESULTS. INDICATION INVEGA SUSTENNA (paliperidone palmitate) is indicated for the treatment of: Schizophrenia. Schizoaffective disorder as monotherapy and as an
More informationREXULTI (brexpiprazole) oral tablet
REXULTI (brexpiprazole) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy
More informationLonasen (Blonanserin) Lullan (Perospirone) Saphris/Sycrest (Asenapine, ORG 5222, SCH ) Saphris/Sycrest (Continued)...
CHAPTER ONE: INTRODUCTION... 1 STUDY GOALS AND OBJECTIVES... 1 REASONS FOR DOING THIS STUDY... 2 INTENDED AUDIENCE... 2 SCOPE OF REPORT... 3 METHODOLOGY... 3 INFORMATION SOURCES... 4 AUTHOR S CREDENTIALS...
More informationWhat Team Members Other Than Prescribers Need To Know About Antipsychotics
What Team Members Other Than Prescribers Need To Know About Antipsychotics The Care Transitions Network National Council for Behavioral Health Montefiore Medical Center Northwell Health New York State
More informationPharmacy Benefit Management (PBM) Program FORMULARY/PRODUCT RESTRICTIONS
Workforce Safety & Insurance Revised Document Date: 07/21/2015 1600 E Century Ave Ste 1 PO Box 5585 Bismarck, ND 58506-5585 701.328.3800 1.800.777.5033 www.workforcesafety.com Pharmacy Benefit Management
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Reference Number: AZ.CP.PHAR.10.11.10 Effective Date: 07.16 Last Review Date: 09.12.18 Line of Business: Medicaid Arizona Revision Log See Important Reminder at the end of this policy
More informationHOSPITAL BASED INPATIENT PSYCHIATRIC SERVICES (HBIPS) MEASURE SET
HOSPITAL BASED INPATIENT PSYCHIATRIC SERVICES (HBIPS) MEASURE SET Kathy Wonderly RN, MSEd, CPHQ Consultant Developed: February, 2013 Most recently revised: December 2018 The Psychiatric Measure Set CMS
More informationAntipsychotic Prior Authorization Request
Antipsychotic Prior Authorization Request Commonwealth of Massachusetts MassHealth Drug Utilization Review Program P.O. Box 2586, Worcester, MA 01613-2586 Fax: 1-877-208-7428 Phone: 1-800-745-7318 MassHealth
More informationIn August 2009, the FDA approved asenapine
For mass reproduction, content licensing and permissions contact Dowden Health Media. p Asenapine for schizophrenia and bipolar I disorder Jana Lincoln, MD, and Sheldon Preskorn, MD In August 2009, the
More informationFebruary 7-9, 2019 The Westin Fort Lauderdale Florida. Provided by
February 7-9, 2019 The Westin Fort Lauderdale Florida Provided by Addressing Your Greatest Concerns in Schizophrenia Management: From Suicide to Relapse Prevention and the Role of LAIs John Lauriello,
More informationRiding the Waves: Tools for the Management of Bipolar Disorder
Riding the Waves: Tools for the Management of Bipolar Disorder Jacintha S. Cauffield, Pharm.D., BCPS, CDE Associate Professor of Pharmacy Practice Palm Beach Atlantic University Lloyd L. Gregory School
More informationAntipsychotics: The Essentials. Module 5: A Primer on Selected Antipsychotics
Antipsychotics: The Essentials Module 5: A Primer on Selected Antipsychotics Slide 1 Recently approved antipsychotics Iloperidone (Fanapt) - 2009 Asenapine (Saphris, Sycrest) - 2009 Lurasidone (Latuda)
More informationLiterature Scan: Parenteral Antipsychotics
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationINDIANA PHARMACISTS ALLIANCE (IPA) CONTINUING PHARMACY EDUCATION. An Update on the Pharmacologic Management of Schizophrenia
An Update on the Pharmacologic Management of Schizophrenia Authors: Thomas R. Smith, PharmD Assistant Professor of Pharmacy Practice Manchester University College of Pharmacy Trsmith03@manchester.edu Mei
More informationDrug Class Review Atypical Antipsychotic Drugs
Drug Class Review Atypical Antipsychotic Drugs Final Update 3 Report July 2010 The purpose of reports is to make available information regarding the comparative clinical effectiveness and harms of different
More informationINJECTABLE ANTIPSYCHOTICS AUTHORIZATION FORM
SUBMIT TO Utilization Management Department Phone: 1.866.912.6285 Fax: 1.866.694.3649 MEMBER INFORMATION INJECTABLE ANTIPSYCHOTICS AUTHORIZATION FORM Fax completed form to Cepatico at 866.694.3649. Upon
More informationJudges Reference Table for the March 2016 Psychotropic Medication Utilization Parameters for Foster Children
Judges Reference Table for the Psychotropic Medication Utilization Parameters for Foster Children Stimulants for treatment of ADHD Preschool (Ages 3-5 years) Child (Ages 6-12 years) Adolescent (Ages 13-17
More informationTable of Contents. 1.0 Policy Statement...1
Division of Medical Assistance General Clinical Policy No. A-6 Table of Contents 1.0 Policy Statement...1 2.0 Policy Guidelines...1 2.1 Eligible Recipients...1 2.1.1 General Provisions...1 2.1.2 EPSDT
More informationInhaled Corticosteroid Dose Comparison in Asthma
This Clinical Resource gives subscribers additional insight related to the Recommendations published in April 2017 ~ Resource #330402 Inhaled Corticosteroid Dose Comparison in Asthma The chart below provides
More informationKelly E. Williams, Pharm.D. PGY2 Psychiatric Pharmacy Resident April 16,2009
Kelly E. Williams, Pharm.D. PGY2 Psychiatric Pharmacy Resident April 16,2009 List the antipsychotics most often prescribed Compare and contrast the use and adverse effects experienced in the pediatric
More informationIntroduction. Objectives. Psychotropic Medications & Cardiometabolic Risk
Psychotropic Medications & Cardiometabolic Risk Sam Ellis, PharmD, BCPS, CDE Associate Professor University of Colorado School of Pharmacy Introduction Second GenerationAntipsychotics (SGA) first FDA approved
More informationRegier 1993; Kessler 2005; Stevens 2016; Parellada 206; Mohr 2012; Prajapati 2016;
Regier 1993; Kessler 2005; Stevens 2016; Parellada 206; Mohr 2012; Prajapati 2016; Miyamoto 2017 Risperdal Consta (risperidone) Zyprexa Relprevv (olanzapine pamoate) Invega Sustenna (paliperidone palmiate)
More informationPsychopharmacologic Updates. Nimisha Gokaldas, MD Medical Director Multnomah County, Mental Health and Addiction Services Division
Psychopharmacologic Updates Nimisha Gokaldas, MD Medical Director Multnomah County, Mental Health and Addiction Services Division This author has NO affiliations with or involvement in any organization
More informationDrugs requiring prior authorization: the list of drugs requiring prior authorization for this clinical criteria
Drug/Drug Class Antipsychotics Clinical Criteria Information Included in this Document Drugs requiring prior authorization: the list of drugs requiring prior authorization for this clinical criteria Prior
More informationClass Update: Oral Antipsychotics
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Rexulti) Reference Number: CP.PMN.68 Effective Date: 11.05.15 Last Review Date: 02.18 Line of Business: Commercial, Health Insurance Marketplace, Medicaid Revision Log See Important Reminder
More informationLATUDA Commercial Update
LATUDA Commercial Update LATUDA Meeting (Tokyo) January 2011 Mark Iwicki President and Chief Operating Officer Sunovion Pharmaceuticals Inc. Sunovion Is Uniquely Positioned to Deliver Strong Performance
More informationLurasidone: A New Antipsychotic For Schizophrenia. Objectives. Introduction. Pharmacology/Pharmacokinetics. Mechanism of Action. Mechanism of Action
Lurasidone: A New Antipsychotic For Schizophrenia Theodore Pikoulas, PharmD PGY2 Psychiatric Pharmacy Resident Louis Stokes Cleveland VAMC Objectives Review the pharmacology and the pharmacokinetics Identify
More informationRexulti (brexpiprazole)
Market DC Rexulti (brexpiprazole) Override(s) Approval Duration Prior Authorization 1 year Quantity Limit *Indiana see State Specific Mandates below *Maryland see State Specific Mandates below *Virginia
More informationZIPRASIDONE. THERAPEUTICS Brands Geodon see index for additional brand names
ZIPRASIDONE THERAPEUTICS Brands Geodon see index for additional brand names Generic? Yes Class Neuroscience-based Nomenclature: dopamine and serotonin receptor antagonist (DS_RAn) Atypical antipsychotic
More informationInitiation and Adjustment of Insulin Regimens for Type 2 Diabetes
Types of Insulin Rapid-acting insulin: lispro (Humalog), aspart (NovoRapid), glulisine (Apidra) Regular short-acting insulin: Humulin R, Novolin ge Toronto, Hypurin Regular Basal insulin: NPH (Humulin
More informationCONTRAINDICATIONS TABLE
CONTRAINDICATIONS TABLE Generic Name Brand Name Contraindications Amphetamine Salts Adderall, Adderall XR Hypersensitivity to amphetamine, dextroamphetamine, or other sympathomimetic amines Advanced arteriosclerosis
More informationPsychotropics and Foster Care: Challenge or Opportunity?
Psychotropics and Foster Care: Challenge or Opportunity? Raymond C. Love, PharmD, BCPP, FASHP Professor and Director, Mental Health Program University of Maryland School of Pharmacy Objectives At the conclusion
More informationClinical Policy: Olanzapine Orally Disintegrating Tablet (Zyprexa Zydis) Reference Number: CP.PMN.29 Effective Date: Last Review Date: 02.
Clinical Policy: (Zyprexa Zydis) Reference Number: CP.PMN.29 Effective Date: 08.01.15 Last Review Date: 02.19 Line of Business: Medicaid See Important Reminder at the end of this policy for important regulatory
More informationImproving Outcomes in Schizophrenia: Long-acting Depots and Long-term Treatment
Improving Outcomes in Schizophrenia: Long-acting Depots and Long-term Treatment page 247 in syllabus Stephen M. Stahl, MD, PhD Adjunct Professor, Department of Psychiatry University of California, San
More informationSchizophrenia Pharmacology UNIVERSITY OF HAWAI I HILO PRE -NURSING PROGRAM
Schizophrenia Pharmacology UNIVERSITY OF HAWAI I HILO PRE -NURSING PROGRAM NURS 203 GENERAL PHARMACOLOGY DANITA NARCISO PHARM D Learning Objectives Understand the result of dopamine binding to D2 receptors
More informationIn February 2013, the FDA approved a
Long-acting injectable aripiprazole for adult schizophrenia Jana Lincoln, MD Depot formulation and once-monthly dosing might improve adherence in patients with schizophrenia 46 May 2013 In February 2013,
More informationCriteria for Child Psychiatrist on the Use of Selected Psychotropic Medications in Children & Adolescents
Criteria for Child Psychiatrist on the Use of Selected Psychotropic Medications in Children & Adolescents DRUG NAME INDICATIONS / ACCEPTABLE USES PRIOR STIMULANT/ADHD DRUGS Daytrana (methylphenidate) ADHD
More informationSchedule FDA & literature based indications
Psychotropic Medication List Recommended dosages are intended to serve only as a guide for children. Recommended doses are literature based. Clinicians should consult package insert of medications for
More informationActivity Overview. Target Audience
Activity Overview In this activity, faculty will introduce a patient with probable schizophrenia. As the details of the case unfold, participants p will explore options for the treatment of the first episode
More informationNumber needed to treat (NNT) is a measure of
For mass reproduction, content licensing and permissions contact Dowden Health Media. p sychiatry Can you interpret confidence intervals? It s not that difficult NNT medicine s secret stat offers infinite
More informationIt is the policy of health plans affiliated with Centene Corporation that Seroquel XR is medically necessary when the following criteria are met:
Clinical Policy: (Seroquel XR) Reference Number: CP.PMN.64 Effective Date: 12.01.14 Last Review Date: 02.18 Line of Business: Commercial, Health Insurance Marketplace, Medicaid Revision Log See Important
More informationAntipsychotics and stroke risk
Integrating Sentinel into Routine Regulatory Drug Review: A Snapshot of the First Year Antipsychotics and stroke risk Lockwood G. Taylor, PhD, MPH Division of Epidemiology II Office of Pharmacovigilance
More informationIs Lurasidone more safe and effective in the treatment ofschizoaffective disorder and schizophrenia than other commonanti-psychotic medications?
Philadelphia College of Osteopathic Medicine DigitalCommons@PCOM PCOM Physician Assistant Studies Student Scholarship Student Dissertations, Theses and Papers 2015 Is Lurasidone more safe and effective
More informationSepsis and Septic Shock: New Definitions for Adults
PL Detail-Document #320424 This PL Detail-Document gives subscribers additional insight related to the Recommendations published in PHARMACIST S LETTER / PRESCRIBER S LETTER April 2016 Sepsis and Septic
More informationPsychiatric Medication Guide
Psychiatric Medication Guide F O R : N E O N P R I M A R Y H E A L T H C A R E P R O V I D E R S B Y : M I C H E L L E R O M E R O, D O M A Y, 2 0 1 3 Anti-depressants TCA s & MAOI s (Tricyclic Antidepressants
More informationQUETIAPINE. THERAPEUTICS Brands Seroquel Seroquel XR see index for additional brand names. Generic? Yes
QUETIAPINE THERAPEUTICS Brands Seroquel Seroquel XR see index for additional brand names Generic? Yes Class Neuroscience-based Nomenclature: dopamine, serotonin multimodal (DS-MM) Atypical antipsychotic
More informationClinician's Guide to Prescribing Depot Antipsychotics
Handout for the Neuroscience Education Institute (NEI) online activity: Clinician's Guide to Prescribing Depot Antipsychotics Learning Objectives Explain the benefits and risks of depot antipsychotics
More informationTreat Schizophrenia Schizoaffective disorder Bipolar disorder Psychotic depression Off-label uses Insomnia Tics Delirium Stuttering
Robert M. Millay RN MSN Ed Professor, Napa Valley College Psychiatric Technician Programs Copyright 2015, 2011, 2007, 2003, 1999, 1995, 1991 by Mosby, an imprint of Elsevier Inc. Treat Schizophrenia Schizoaffective
More informationFor personal use only
For mass reproduction, content licensing and permissions contact Dowden Health Media. Copyright Dowden Health Media For personal use only Clozapine, despite its side effect burden, may be the most effective
More informationNew Exception Status Benefits
AUGUST 2017 Nova Scotia Formulary Updates New Exception Status Benefits Forxiga (dapagliflozin) Xigduo (dapagliflozin and metformin hydrochloride) Criteria Update: Antipsychotic Medications Abilify (aripiprazole)
More informationPharmacotherapy of psychosis and schizophrenia in youth
Pharmacotherapy of psychosis and schizophrenia in youth Benedetto Vitiello Pavia, 2 December 2017 Disclosure Benedetto Vitiello, M.D. Professor of Child and Adolescent Neuropsychiatry University of Turin,
More informationschizophrenia with An early stage of distinct treatment needs MANAGING FIRST-EPISODE PSYCHOSIS
F I R S T O F 2 P A R T S MANAGING FIRST-EPISODE PSYCHOSIS An early stage of schizophrenia with distinct treatment needs Minimize duration of untreated ; aim for remission Kristen N. Gardner, PharmD PGY-2
More informationDevon A. Sherwood, PharmD, BCPP Assistant Professor of Pharmacy Practice
Devon A. Sherwood, PharmD, BCPP Assistant Professor of Pharmacy Practice Differentiate dopamine neurotransmitter pathways associated with antipsychotic medications Identify therapy challenges associated
More informationMeasure #383 (NQF 1879): Adherence to Antipsychotic Medications For Individuals with Schizophrenia National Quality Strategy Domain: Patient Safety
Measure #383 (NQF 1879): Adherence to Antipsychotic Medications For Individuals with Schizophrenia National Quality Strategy Domain: Patient Safety 2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY
More informationApril 2016 Prepared By: Kimberly D. Griego, PharmD, CGP
April 2016 Prepared By: Kimberly D. Griego, PharmD, CGP Bipolar disorder (BD), also referred to as manic-depression, presents with dramatic swings in a person s mood and energy level, which affects their
More informationObjectives. Pre Discussion Question #2. Disparity in Care Demographics
Objectives Implementation of a pharmacist driven metabolic monitoring protocol for second generation antipsychotics (SGAs) Jonathan Willett, PharmD PGY 1 Pharmacy Practice Resident Chickasaw Nation March
More informationTexas Standard Prior Authorization Form Addendum
Texas Standard Prior Authorization Form Addendum Molina Healthcare of Texas Antipsychotics (Medicaid) This fax machine is located in a secure location as required by HIPAA Regulations. Complete / Review
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Single Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Single Technology Appraisal Aripiprazole for the treatment and prevention of acute manic and mixed episodes in bipolar disorder in children and adolescents
More informationTexas Prior Authorization Program Clinical Edit Criteria
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document Drugs requiring prior authorization: the list of drugs requiring prior authorization
More information